MB09,一个denosumab生物相似的候选者:在健康受试者的I期研究中证明生物相似性
Monika Tomaszewska-Kiecana1, Elisabete Carapuça2, Amalia Florez-Igual2
1Biokinetica S.A., Józefów, Poland.
Clinical and translational science
|August 29, 2024
概括
这项研究表明,MB09是一种denosumab生物类似剂,具有类似的药理动力学和药理动力学,以参考denosumab. MB09是安全的,耐受性良好,免疫原性,支持其生物相似性.
科学领域:
- 药理学 药理学 是一个学科.
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 德诺苏马布是一种生物药物,用于治疗各种与骨相关的疾病.
- 生物类似候选药物旨在为参考生物制剂提供安全有效的替代品.
研究的目的:
- 为了评估MB09 (denosumab生物类似候选物) 和参考denosumab之间的药理动力学 (PK) 相似性.
- 与参考denosumab相比,评估MB09的药理学,安全性和免疫性概况.
主要方法:
- 一期,随机,双盲,三臂,单剂量,并行研究,对255名健康男性进行.
- 35毫克MB09或参考denosumab的皮下使用.
- 主要PK终点:AUC0-last和Cmax;次要终点包括药理动力学,安全性和免疫性.
主要成果:
- 对于MB09的全身暴露 (AUC0-last,Cmax) 相当于参考denosumab的暴露.
- 药理学参数和终端半衰期在治疗手臂中是相似的.
- MB09的安全性和免疫性概况相对较低.
结论:
- 根据PK,PD,安全性和免疫性,MB09与参考代诺苏马布具有生物相似性.
- 这些发现支持MB09作为一个可行的治疗选择.
- 这项研究为德诺苏马布生物相似性提供了有力的证据.
相关概念视频
Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
556
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
556
Bioavailability Study Design: Single Versus Multiple Dose Studies
339
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
339
Bioavailability Study Design: Healthy Subjects Versus Patients
213
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
213
Bioequivalence studies: Biowaivers
401
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
401
Drug Products: Biologics, Biosimilars and Interchangeables
357
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
357


